Ten63 Therapeutics
PrivateLast Round
Strategic
Feb 19, 2026
Total Funding Raised
$72.75M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Ten63 Therapeutics is a biotechnology company that develops small molecule therapeutics for challenging disease targets, primarily in oncology, using its proprietary AI-driven drug discovery platform, BEYOND.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ten63 Therapeutics Comparables
Compare Ten63 Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Qubit Pharmaceuticals | 86% | |
| Genesis Molecular AI | 84% | |
| Aqemia | 82% |
Ten63 Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Feb 19, 2026 | ||||
| Strategic | Feb 19, 2026 | ||||
| Series A | May 2, 2023 | ||||
| Seed | Jan 27, 2021 | ||||
| Accelerator | Jun 25, 2019 | ||||
Seed | Apr 5, 2019 |
Key People
Founding team and executive leadership
Ten63 Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hatteras Venture Partners | Strategic, Series A |
| Gates Foundation | Strategic |
| Chugai Venture Fund | Strategic |
| RYSE Asset Management | Strategic |
| Panorama Point Partners | Strategic |
| K5 Global | Strategic |
| Bill & Melinda Gates Foundation | Strategic |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 24, 2026
Open roles increased to 7, 2.1x the trailing average.
- Jul 13, 2026
Open roles increased from 0 to 5, representing 16% of headcount.
Ten63 Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Ten63 Therapeutics's valuation, stock price, and market status.
Is Ten63 Therapeutics a public or private company?
Ten63 Therapeutics is a private company.
What is the current stock price of Ten63 Therapeutics?
Ten63 Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Ten63 Therapeutics worth (valuation)?
Valuation information for Ten63 Therapeutics is not publicly available.
Can I buy Ten63 Therapeutics stock?
Ten63 Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Ten63 Therapeutics's last funding round?
Ten63 Therapeutics's most recent funding round was Strategic on February 19, 2026.
Who are the main investors in Ten63 Therapeutics?
Key investors in Ten63 Therapeutics include Hatteras Venture Partners, Gates Foundation, Chugai Venture Fund, Morpheus Ventures.
Will Ten63 Therapeutics IPO soon?
No public IPO plans have been announced for Ten63 Therapeutics.
How can I track Ten63 Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ten63 Therapeutics's secondary market activity and sign up for updates.